Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.195
+0.065 (5.75%)
At close: Jun 26, 2026, 4:00 PM EDT
1.180
-0.015 (-1.26%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Company Description
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally.
It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
The company is headquartered in London, the United Kingdom.
Tiziana Life Sciences Ltd
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Ivor Elrifi |
Contact Details
Address: 14/15 Conduit Street London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivor R. Elrifi Ph.D. | Chief Executive Officer and Executive Director |
| Gabriele Marco Antonio Cerrone M.B.A. | Founder and Executive Chairman |
| Keeren Shah | Chief Operating Officer and Chief Financial Officer |
| William Edward Tente M.S. | Chief Regulatory Officer |
| Dr. Richard K. Kim M.D. | Chief Medical Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 6-K | Report of foreign issuer |
| Jun 15, 2026 | 6-K | Report of foreign issuer |
| May 28, 2026 | 6-K | Report of foreign issuer |
| May 21, 2026 | 6-K | Report of foreign issuer |
| May 19, 2026 | 6-K | Report of foreign issuer |
| May 14, 2026 | 6-K | Report of foreign issuer |
| May 1, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 30, 2026 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 16, 2026 | 6-K | Report of foreign issuer |
| Apr 14, 2026 | 6-K | Report of foreign issuer |